Noriko Motoi

13.2k citations

191 papers · 5.7k indexed · 2 hit papers · h-index 32

Pulmonary and Respiratory Medicine top 0.5%
Oncology top 1%
Molecular Biology top 5%
Cancer Research top 2%
Radiology, Nuclear Medicine and Imaging top 2%

Co-authors: William D. Travis William L. Gerald Valerie W. Rusch Gregory J. Riely Mark G. Kris Akihiko Yoshizawa Bernard J. Park Cami S. Sima
Topics: Lung Cancer Treatments and Mutations (66 papers)Lung Cancer Diagnosis and Treatment (37 papers)Lung Cancer Research Studies (33 papers)
Cited by: Pulmonary and Respiratory Medicine Oncology Microbiology
Journals: Journal of Clinical Investigation Nature Genetics Journal of Clinical Oncology
Partner nations: Japan United States United Kingdom

In The Last Decade

Noriko Motoi

172 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

2011 757 citations Akihiko Yoshizawa, Noriko Motoi et al. profile →
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

2007 535 citations Noriko Motoi et al. profile →

Peers

Countries citing papers authored by Noriko Motoi

Since Specialization

Citations

This map shows the geographic impact of Noriko Motoi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noriko Motoi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noriko Motoi more than expected).

Fields of papers citing papers by Noriko Motoi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noriko Motoi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noriko Motoi. The network helps show where Noriko Motoi may publish in the future.

Co-authorship network of co-authors of Noriko Motoi

This figure shows the co-authorship network connecting the top 25 collaborators of Noriko Motoi. A scholar is included among the top collaborators of Noriko Motoi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noriko Motoi. Noriko Motoi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma 2024 ·Cancer Science ·Kotaro Sugawara,Takashi Fukuda,Chiaki Murakami,(unknown),Takako Yoshii,(unknown),(unknown),Yasuhito Kobayashi,Hiroki Hara,Hiroaki Kanda,Noriko Motoi	5
2	Clinicopathological characteristics and molecular analysis of lung cancer associated with ciliated muconodular papillary tumor/bronchiolar adenoma 2023 ·Pathology International ·(unknown),Noriko Motoi,Masaya Yotsukura,Yukihiro Yoshida,Kazuo Nakagawa,Shigehiro Yagishita,Masayuki Shirasawa,Tsutomu Yoshida,Kouya Shiraishi,Takashi Kohno,Yuichiro Ohe,Shun‐ichi Watanabe	2
3	Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC 2023 ·JTO Clinical and Research Reports ·(unknown),Tatsuya Yoshida,Shigehiro Yagishita,(unknown),Yuji Matsumoto,Yuki Shinno,Yusuke Okuma,Yasushi Goto,Hidehito Horinouchi,Noboru Yamamoto,Kazuhisa Takahashi,Noriko Motoi,Akinobu Hamada,Yuichiro Ohe	3
4	Prevalence and diagnostic significance of non‐invasive follicular thyroid neoplasm with papillary‐like nuclear features in Japan—A multi‐institutional study 2023 ·Pathology International ·Mitsuyoshi Hirokawa,(unknown),Noriko Motoi,Tomohiro Chiba,(unknown),Hironao Yasuoka,Rumi Hino,Miyoko Higuchi,Akira Miyauchi,Takashi Akamizu	0
5	Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy 2023 ·Cancers ·Tomohiro Tanaka,Yasushi Goto,Masafumi Horie,Ken Masuda,Yuki Shinno,Yuji Matsumoto,Yusuke Okuma,Tatsuya Yoshida,Hidehito Horinouchi,Noriko Motoi,Yasushi Yatabe,Shun‐ichi Watanabe,Noboru Yamamoto,Yuichiro Ohe	2
6	Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients 2022 ·Clinical Lung Cancer ·(unknown),Ryota Shibaki,Tatsuya Yoshida,Shuji Murakami,(unknown),(unknown),Yuji Matsumoto,Ken Masuda,Yuki Shinno,Yusuke Okuma,Yasushi Goto,Hidehito Horinouchi,Noboru Yamamoto,Yuichiro Ohe,Noriko Motoi	13
7	“Real” Tumor-Spread Through Air Spaces of Lung Adenocarcinoma Presented Intrapulmonary Metastases Through Bronchiole Air Spaces: A Case Report 2022 ·JTO Clinical and Research Reports ·(unknown),Noriko Motoi,Hirokazu Watanabe,Yukihiro Yoshida,Shun‐ichi Watanabe,Masahiko Kusumoto	4
8	Cytology Reporting System for Lung Cancer from the Japan Lung Cancer Society and the Japanese Society of Clinical Cytology: An Extensive Study Containing More Benign Lesions 2021 ·Acta Cytologica ·Akihiko Yoshizawa,Kenzo Hiroshima,Akemi Takenaka,Reiji Haba,Kunimitsu Kawahara,Yuko Minami,(unknown),(unknown),Shinji Miyake,(unknown),(unknown),(unknown),(unknown),Masayuki Mano,Jun Matsubayashi,Noriko Motoi,Toshitaka Nagao,Shin‐ichi Nakatsuka,Tsutomu Yoshida,Yukitoshi Satoh	10
9	Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer 2021 ·European Journal of Cancer ·Masayuki Shirasawa,Tatsuya Yoshida,Tatsuya Imabayashi,Kae Okuma,Yuji Matsumoto,Ken Masuda,Yuki Shinno,Yusuke Okuma,Yasushi Goto,Hidehito Horinouchi,Takaaki Tsuchida,Noboru Yamamoto,Yuko Nakayama,Shun‐ichi Watanabe,Noriko Motoi,Yuichiro Ohe	21
10	Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations 2021 ·Molecular Cancer Therapeutics ·(unknown),Shigehiro Yagishita,Yoshiharu Hayashi,(unknown),Mikiko Suzuki,Shinji Kohsaka,Toshihide Ueno,Yuji Matsumoto,Hidehito Horinouchi,Yuichiro Ohe,Shun‐ichi Watanabe,Noriko Motoi,Yasushi Yatabe,Hiroyuki Mano,Kazuhisa Takahashi,Akinobu Hamada	6
11	P63-negative pulmonary NUT carcinoma arising in the elderly: a case report 2020 ·Diagnostic Pathology ·(unknown),Koji Saito,Noriko Motoi,Taisuke Mori,Yuichi Saito,(unknown),(unknown),(unknown),(unknown),Yoshikane Yamauchi,Yukinori Sakao,Hiroshi Uozaki,Masafumi Kawamura	11
12	Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer 2020 ·European Journal of Cancer ·Masayuki Shirasawa,Tatsuya Yoshida,Yuji Matsumoto,Yuki Shinno,Yusuke Okuma,Yasushi Goto,Hidehito Horinouchi,Noboru Yamamoto,Shun‐ichi Watanabe,Yuichiro Ohe,Noriko Motoi	15
13	Cytology Reporting System for Lung Cancer from the Japan Lung Cancer Society and Japanese Society of Clinical Cytology: An Interobserver Reproducibility Study and Risk of Malignancy Evaluation on Cytology Specimens 2020 ·Acta Cytologica ·Kenzo Hiroshima,Akihiko Yoshizawa,Akemi Takenaka,Reiji Haba,Kunimitsu Kawahara,Yuko Minami,(unknown),(unknown),Shinji Miyake,(unknown),Kana Miyamoto,(unknown),(unknown),Masayuki Mano,Jun Matsubayashi,Noriko Motoi,Toshitaka Nagao,Shin‐ichi Nakatsuka,Tsutomu Yoshida,Yukitoshi Satoh	21
14	Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib 2020 ·Lung Cancer ·Toshiaki Takahashi,(unknown),(unknown),Tatsuya Yoshida,Noriko Motoi,Yuichiro Ohe	4
15	CD20⁺ tumor‐infiltrating immune cells and CD204⁺ M2 macrophages are associated with prognosis in thymic carcinoma 2020 ·Cancer Science ·Jun Sato,Shigehisa Kitano,Noriko Motoi,Yoshinori Ino,Noboru Yamamoto,Shun‐ichi Watanabe,Yuichiro Ohe,Nobuyoshi Hiraoka	32
16	Large pulmonary sclerosing pneumocytoma with massive necrosis and vascular invasion: a case report 2019 ·Oxford Medical Case Reports ·Takashi Sakai,Tomohiro Miyoshi,Shigeki Umemura,Jun Suzuki,Shoko Nakasone,Satoshi Okada,Kenta Tane,Keiju Aokage,Kōichi Goto,Noriko Motoi,Genichiro Ishii,Masahiro Tsuboi	8
17	Stromal tiny black dots, like “sugar‐coated”, of von Kossa stain is a diagnostic clue to hyalinizing trabecular tumor of the thyroid gland 2018 ·Pathology International ·Rumi Hino,Noriko Motoi,(unknown),Aya Ebina,Keiko Yamada,Miyoko Higuchi,Mitsuyoshi Hirokawa,Yuichi Ishikawa	5
18	Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer 2018 ·Lung Cancer ·(unknown),Shintaro Kanda,Yasushi Goto,Hidehito Horinouchi,Yutaka Fujiwara,Noboru Yamamoto,Noriko Motoi,Yuichiro Ohe	58
19	A case of inflammatory myofibroblastic tumor diagnosed by thoracoscopic resection : A case report 2013 ·The Journal of the Japanese Society of Clinical Cytology ·Noriko Yanagitani,Keita Kudo,(unknown),(unknown),Noriko Motoi,Yuichi Ishikawa,Takeshi Horai	0
20	Intrinsic Cooperation between p16INK4a and p21Waf1/Cip1 in the Onset of Cellular Senescence and Tumor Suppression In vivo 2010 ·Cancer Research ·(unknown),Akiko Takahashi,Noriko Motoi,Shin Yoshimoto,Tomoko Tajima,Kimi Yamakoshi,Atsushi Hirao,Shigeru Yanagi,Kiyoko Fukami,Yuichi Ishikawa,Saburo Sone,Eiji Hara,Naoko Ohtani	94

About Noriko Motoi

Noriko Motoi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Rheumatology, having authored 191 papers that have together received 5.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (66 papers), Lung Cancer Diagnosis and Treatment (37 papers) and Lung Cancer Research Studies (33 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (3.3k citations), Oncology (2.6k citations) and Microbiology (51 citations). Noriko Motoi has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include William D. Travis, William L. Gerald, Valerie W. Rusch, Gregory J. Riely, Mark G. Kris, Akihiko Yoshizawa, Bernard J. Park, Cami S. Sima, Sakae Okumura and William Pao. Their work appears in journals such as Journal of Clinical Investigation, Nature Genetics and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact